Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSZ0H9)

Drug Name
2-(3,4-Dihydroxyphenyl)Acetic Acid Drug Info
Synonyms
3,4-Dihydroxyphenylacetic acid; 102-32-9; Dopac; Homoprotocatechuic acid; 2-(3,4-DIHYDROXYPHENYL)ACETIC ACID; Dopacetic acid; Benzeneacetic acid, 3,4-dihydroxy-; 3,4-Dihydroxybenzeneacetic acid; Dihydroxyphenylacetic acid; 4-Carboxymethylcatechol; (3,4-DIHYDROXYPHENYL)ACETIC ACID; Homoprotocatechuate; 3,4-Dihydroxy-phenylacetic acid; Acetic acid, (3,4-dihydroxyphenyl)-; BA 2773; UNII-KEX5N0R4N5; CCRIS 3765; 3,4-dihydroxyphenylacetate; Lopac-D-9128; EINECS 203-024-1; NSC 73191; BRN 2211017; KEX5N0R4N5; 3,4-DHPOP; MLS001056737
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
547
ChEBI ID
CHEMBL1284
CAS Number
CAS 102-32-9
TTD Drug ID
DMSZ0H9

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Human Deoxyribonucleic acid (hDNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [2]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [3]
Daunorubicin DMQUSBT Acute monocytic leukemia Approved [4]
Ifosfamide DMCT3I8 Adult central nervous system germ cell tumor Approved [5]
Cyclophosphamide DM4O2Z7 Advanced cancer 2A00-2F9Z Approved [6]
Carboplatin DMG281S Adenocarcinoma 2D40 Approved [7]
Busulfan DMXYJ9C Chronic myelogenous leukaemia 2A20.0 Approved [8]
Procarbazine DMIK367 Hodgkin lymphoma 2B30 Approved [9]
Dactinomycin DM2YGNW Adult kidney Wilms tumor Approved [10]
Dacarbazine DMNPZL4 Adenocarcinoma 2D40 Approved [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Inhibitor [1]

References

1 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2 Cisplatin and DNA repair in cancer chemotherapy.Trends Biochem Sci.1995 Oct;20(10):435-9.
3 Structures of oxaliplatin-oligonucleotide adducts from DNA.J Mass Spectrom.2012 Oct;47(10):1282-93.
4 31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12.
5 Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35.
6 O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22.
7 Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905.
8 DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci. 2004 May;95(5):454-8.
9 Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations... DNA Repair (Amst). 2009 Jan 1;8(1):72-86.
10 Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215.
11 Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mono... Melanoma Res. 2011 Dec;21(6):502-8.